Volume 28, Number 3—March 2022
Research
Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda
Table 3
Country and study site | No. specimens at enrollment* | No. (%) specimens detected with pfhrp2–/pfhrp3– | No. (%) specimens detected with pfhrp2–/pfhrp3+ | No. (%) specimens detected with pfhrp2+/pfhrp3– |
---|---|---|---|---|
Ethiopia | ||||
Arba Minch | 15 | 0 | 0 | 2 (13.3) |
Pawe |
132 |
3 (2.3) |
2 (1.5) |
2 (1.5) |
Kenya | ||||
Siaya |
332 |
0 |
0 |
0 |
Madagascar | ||||
Ankazomborona | 168 | 0 | 3 (1.8) | 1 (0.6) |
Antsenavolo | 54 | 0 | 0 | 0 |
Kianjavato | 116 | 0 | 0 | 0 |
Matanga | 172 | 0 | 0 | 0 |
Vohitromby |
110 |
0 |
1 (0.9) |
0 |
Rwanda | ||||
Bugarama | 88 | 0 | 0 | 1 (1.1) |
Masaka | 42 | 0 | 0 | 0 |
Rukara | 88 | 0 | 0 | 0 |
*Percentages may underestimate the actual amount of deleted parasites because not all samples were genotyped, rather only those found to initially have depressed histidine-rich protein 2 levels. All samples with high histidine-rich protein 2 signal assumed to be from wild-type infections.
Page created: January 12, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.